U.S. budget impact analysis of biosimilar versus originator intravenous rituximab for the treatment of non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA).

Elizabeth James,Holly Trautman,Ali McBride,Azhar Choudhry,Stephen J. Thompson

U.S. budget impact analysis of biosimilar versus originator intravenous rituximab for the treatment of non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA).

2021

Elizabeth James
Holly Trautman
Ali McBride
Azhar Choudhry
Stephen J. Thompson

e18820Background: Rituximab-abbs is an anti-CD20 monoclonal antibody and an important immuno-oncology agent for the treatment of B-cell malignancies NHL (diffuse large B-cell lymphoma [DLBCL] and f...

Keywords:

Granulomatosis with polyangiitis
Gastroenterology
Medicine
Rheumatoid arthritis
Monoclonal antibody
Internal medicine
Chronic lymphocytic leukemia
Rituximab
Lymphoma
Microscopic polyangiitis
Biosimilar

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations